- Home
- XENE
as 05-08-2025 4:00pm EST
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Upcoming Earnings Alert:
Get ready for potential market movements as Xenon Pharmaceuticals Inc. XENE prepares to release earnings report on 12 May 2025.
| Founded: | 1996 | Country: | Canada |
| Employees: | N/A | City: | BURNABY |
| Market Cap: | 2.5B | IPO Year: | 2014 |
| Target Price: | $56.22 | AVG Volume (30 days): | 862.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.74 - $46.00 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1553.36% |
Latest Xenon Pharmaceuticals Inc. News
XENE Breaking Stock News: Dive into XENE Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Chardan Initiates Xenon Pharmaceuticals at Buy With $55 Price Target
GlobeNewswire
3 days ago
Xenon to Report Q1 2025 Financial Results on May 12, 2025
Zacks
4 days ago
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?
GlobeNewswire
6 days ago
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
GlobeNewswire
2 months ago
Xenon to Present at Stifel 2025 Virtual CNS Forum
MT Newswires
2 months ago
RBC Capital Adjusts Xenon Pharmaceuticals Price Target to $58 From $56, Maintains Outperform - Speculative Risk Rating
Zacks
2 months ago
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
Compare XENE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XENE Xenon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.